Ionis Pharmaceuticals (IONS) Receives a Buy from H.C. Wainwright

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Ionis Pharmaceuticals, with a price target of $110.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Kapoor covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Halozyme, and Ionis Pharmaceuticals. According to TipRanks, Kapoor has an average return of 11.7% and a 41.86% success rate on recommended stocks.

In addition to H.C. Wainwright, Ionis Pharmaceuticals also received a Buy from Piper Sandler’s Allison Bratzel in a report issued on February 27. However, on February 28, TipRanks – xAI reiterated a Hold rating on Ionis Pharmaceuticals (NASDAQ: IONS).

Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $203 million and a GAAP net loss of $229 million. In comparison, last year the company earned a revenue of $226.58 million and had a GAAP net loss of $104.35 million

Based on the recent corporate insider activity of 136 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IONS in relation to earlier this year. Last month, Frank C. Bennett, the EVP, Chief Scientific Officer of IONS sold 85,089.00 shares for a total of $7,055,488.77.